Top

Published in:

01-09-2012 | Singapore Immunology Network

Immune predictors of cancer progression

Authors: Benjamin Toh, Valerie Chew, Xilei Dai, Karen Khoo, Muly Tham, Lu-En Wai, Sandra Hubert, Sumathy Velumani, Liang Zhi, Caleb Huang, Jean-Pierre Abastado

Published in: Immunologic Research | Issue 1-3/2012

Abstract

The immune system has multiple, complex, and sometimes opposing roles during cancer progression. While immune-compromised individuals have a higher incidence of cancers, inflammation is also associated with increased risk of disease progression. It is becoming apparent that simple measures of immune responses in the blood are of limited use in cancer. Instead, the importance of the exact identity and functional characteristics of tumor-infiltrating immune cells is increasingly recognized. This realization has led to recent studies that have revealed a critical role for chemokine expression in the tumor microenvironment and suggested a therapeutic potential of manipulating intratumoral expression of chemokines to alter the local immune milieu.

Pazdur R, Wagman L, Camphausen K, Hoskins W. Cancer management: a multidisciplinary approach. 11th ed. Huntington: PRR; 2008.

Edlich RF, Winters KL, Cox MJ, Becker DG, Horowitz JH, Nichter LS, Britt LD, Edlich TJ III, Long WB. National health strategies to reduce sun exposure in Australia and the United States. J Long Term Eff Med Implant. 2004;14(3):215–24. Epub 2004/08/11.CrossRef

Ginsberg GM, Edejer TT, Lauer JA, Sepulveda C. Screening, prevention and treatment of cervical cancer: a global and regional generalized cost-effectiveness analysis. Vaccine. 2009;27(43):6060–79. doi:10.1016/j.vaccine.2009.07.026. Epub 2009/08/04.PubMedCrossRef

Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Stewart ST, Bhatnagar V, Sweeney CJ, Stahl JE, McMahon PM. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA. 2010;304(21):2373–80. doi:10.1001/jama.2010.1720. Epub 2010/12/02.PubMedCrossRef

Jorgensen KJ, Gotzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ. 2009;339:b2587. Epub 2009/07/11.PubMedCrossRef

Tham M, Abastado J. Escape of tumor immune surveillance and metastasis. Drug Discov Today: Dis Models. 2011;8:81–6.CrossRef

Lengagne R, Graff-Dubois S, Garcette M, Renia L, Kato M, Guillet JG, Engelhard VH, Avril MF, Abastado JP, Prevost-Blondel A. Distinct role for CD8 T cells toward cutaneous tumors and visceral metastases. J Immunol. 2008;180(1):130–7.PubMed

Kato M, Takahashi M, Akhand AA, Liu W, Dai Y, Shimizu S, Iwamoto T, Suzuki H, Nakashima I. Transgenic mouse model for skin malignant melanoma. Oncogene. 1998;17(14):1885–8.PubMedCrossRef

Newberg MH, Smith DH, Haertel SB, Vining DR, Lacy E, Engelhard VH. Importance of MHC class 1 alpha2 and alpha3 domains in the recognition of self and non-self MHC molecules. J Immunol. 1996;156(7):2473–80.PubMed

10.

Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol. 2006;24:175–208. doi:10.1146/annurev.immunol.24.021605.090733. Epub 2006/03/23.PubMedCrossRef

11.

Eyles J, Puaux AL, Wang X, Toh B, Prakash C, Hong M, Tan TG, Zheng L, Ong LC, Jin Y, Kato M, Prevost-Blondel A, Chow P, Yang H, Abastado JP. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest. 2010;120(6):2030–9.PubMedCrossRef

12.

Dragani TA, Peissel B, Zanesi N, Aloisi A, Dai Y, Kato M, Suzuki H, Nakashima I. Mapping of melanoma modifier loci in RET transgenic mice. Jpn J Cancer Res. 2000;91(11):1142–7.PubMedCrossRef

13.

Toh B, Wang X, Keeble J, Sim WJ, Khoo K, Wong WC, Kato M, Prevost-Blondel A, Thiery JP, Abastado JP. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol. 2011;9(9):e1001162. doi:10.1371/journal.pbio.1001162PBIOLOGY-D-11-02093. Epub 2011/10/08.PubMedCrossRef

14.

Lienard D, Rimoldi D, Marchand M, Dietrich PY, van Baren N, Geldhof C, Batard P, Guillaume P, Ayyoub M, Pittet MJ, Zippelius A, Fleischhauer K, Lejeune F, Cerottini JC, Romero P, Speiser DE. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun. 2004;4:4. Epub 2004/05/20.PubMed

15.

Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10(9):909–15.PubMedCrossRef

16.

Lengagne R, Le Gal FA, Garcette M, Fiette L, Ave P, Kato M, Briand JP, Massot C, Nakashima I, Renia L, Guillet JG, Prevost-Blondel A. Spontaneous vitiligo in an animal model for human melanoma: role of tumor-specific CD8⁺ T cells. Cancer Res. 2004;64(4):1496–501.PubMedCrossRef

17.

Hong M, Puaux AL, Huang C, Loumagne L, Tow C, Mackay C, Kato M, Prevost-Blondel A, Avril MF, Nardin A, Abastado JP. Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T cell infiltration and tumor control. Cancer Res. 2011;. doi:10.1158/0008-5472.CAN-11-1466. Epub 2011/09/29.

18.

Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006;6(10):715–27. doi:10.1038/nri1936. Epub 2006/09/16.PubMedCrossRef

19.

Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162–74. doi:10.1038/nri2506. Epub 2009/02/07.PubMedCrossRef

20.

Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009;182(8):4499–506.PubMedCrossRef

21.

Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, Bronte V. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol. 2010;22(2):238–44. doi:10.1016/j.coi.2010.01.021. Epub 2010/02/23.PubMedCrossRef

22.

Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K, Katsaros D, O’Brien-Jenkins A, Gimotty PA, Coukos G. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med. 2008;14(1):28–36. doi:10.1038/nm1699. Epub 2007/12/25.PubMedCrossRef

23.

Trimble CL, Clark RA, Thoburn C, Hanson NC, Tassello J, Frosina D, Kos F, Teague J, Jiang Y, Barat NC, Jungbluth AA. Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium. J Immunol. 2010;185(11):7107–14. doi:10.4049/jimmunol.1002756. Epub 2010/11/03.PubMedCrossRef

24.

Chew V, Chen J, Lee D, Loh E, Lee J, Lim KH, Weber A, Slankamenac K, Poon RT, Yang H, Ooi LL, Toh HC, Heikenwalder M, Ng IO, Nardin A, Abastado JP. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut. 2011;. doi:10.1136/gutjnl-2011-300509. Epub 2011/09/21.PubMed

25.

Nardin A, Wong WC, Tow C, Molina TJ, Tissier F, Audebourg A, Garcette M, Caignard A, Avril MF, Abastado JP, Prevost-Blondel A. Dacarbazine promotes stromal remodeling and lymphocyte infiltration in cutaneous melanoma lesions. J Invest Dermatol. 2011;131(9):1896–905. doi:10.1038/jid.2011.128. Epub 2011/06/10.PubMedCrossRef

26.

Hong M, Abastado J. How to develop better screens for anti-cancer therapies? OncoImmunology. 2012;1(3).

Title: Immune predictors of cancer progression
Authors: Benjamin Toh
Valerie Chew
Xilei Dai
Karen Khoo
Muly Tham
Lu-En Wai
Sandra Hubert
Sumathy Velumani
Liang Zhi
Caleb Huang
Jean-Pierre Abastado
Publication date: 01-09-2012
Publisher: Springer-Verlag
Published in: Immunologic Research / Issue 1-3/2012
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-012-8288-4

At a glance: The STEP trials

Springer Medicine

Immune predictors of cancer progression

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1-3/2012

Dendritic cells and the malaria pre-erythrocytic stage

Systematic and systemic immunology: on the future of research and its applications

Complexity and dynamics of host–fungal interactions

Human poly- and cross-reactive anti-viral antibodies and their impact on protection and pathology

The rhapsody of NLRPs: master players of inflammation … and a lot more

The specialized roles of immature and mature dendritic cells in antigen cross-presentation